184 related articles for article (PubMed ID: 23110441)
1. MS2 viruslike particles: a robust, semisynthetic targeted drug delivery platform.
Galaway FA; Stockley PG
Mol Pharm; 2013 Jan; 10(1):59-68. PubMed ID: 23110441
[TBL] [Abstract][Full Text] [Related]
2. Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids.
Wu M; Sherwin T; Brown WL; Stockley PG
Nanomedicine; 2005 Mar; 1(1):67-76. PubMed ID: 17292060
[TBL] [Abstract][Full Text] [Related]
3. Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles.
Pan Y; Zhang Y; Jia T; Zhang K; Li J; Wang L
FEBS J; 2012 Apr; 279(7):1198-208. PubMed ID: 22309233
[TBL] [Abstract][Full Text] [Related]
4. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.
Ashley CE; Carnes EC; Phillips GK; Durfee PN; Buley MD; Lino CA; Padilla DP; Phillips B; Carter MB; Willman CL; Brinker CJ; Caldeira Jdo C; Chackerian B; Wharton W; Peabody DS
ACS Nano; 2011 Jul; 5(7):5729-45. PubMed ID: 21615170
[TBL] [Abstract][Full Text] [Related]
5. Production in Saccharomycescerevisiae of MS2 virus-like particles packaging functional heterologous mRNAs.
Legendre D; Fastrez J
J Biotechnol; 2005 May; 117(2):183-94. PubMed ID: 15823407
[TBL] [Abstract][Full Text] [Related]
6. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
Spagnou S; Miller AD; Keller M
Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141
[TBL] [Abstract][Full Text] [Related]
7. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide.
Wei B; Wei Y; Zhang K; Wang J; Xu R; Zhan S; Lin G; Wang W; Liu M; Wang L; Zhang R; Li J
Biomed Pharmacother; 2009 May; 63(4):313-8. PubMed ID: 18823738
[TBL] [Abstract][Full Text] [Related]
8. The three-dimensional structure of genomic RNA in bacteriophage MS2: implications for assembly.
Toropova K; Basnak G; Twarock R; Stockley PG; Ranson NA
J Mol Biol; 2008 Jan; 375(3):824-36. PubMed ID: 18048058
[TBL] [Abstract][Full Text] [Related]
9. A novel delivery platform based on Bacteriophage MS2 virus-like particles.
Fu Y; Li J
Virus Res; 2016 Jan; 211():9-16. PubMed ID: 26415756
[TBL] [Abstract][Full Text] [Related]
10. Cell-specific delivery of bacteriophage-encapsidated ricin A chain.
Wu M; Brown WL; Stockley PG
Bioconjug Chem; 1995; 6(5):587-95. PubMed ID: 8974458
[TBL] [Abstract][Full Text] [Related]
11. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery.
Shen Y; Wang B; Lu Y; Ouahab A; Li Q; Tu J
Int J Pharm; 2011 Jul; 414(1-2):233-43. PubMed ID: 21545832
[TBL] [Abstract][Full Text] [Related]
12. PRR1 coat protein binding to its RNA translational operator.
Persson M; Tars K; Liljas L
Acta Crystallogr D Biol Crystallogr; 2013 Mar; 69(Pt 3):367-72. PubMed ID: 23519411
[TBL] [Abstract][Full Text] [Related]
13. RNA bacteriophage capsid-mediated drug delivery and epitope presentation.
Brown WL; Mastico RA; Wu M; Heal KG; Adams CJ; Murray JB; Simpson JC; Lord JM; Taylor-Robinson AW; Stockley PG
Intervirology; 2002; 45(4-6):371-80. PubMed ID: 12602361
[TBL] [Abstract][Full Text] [Related]
14. One-plasmid double-expression His-tag system for rapid production and easy purification of MS2 phage-like particles.
Mikel P; Vasickova P; Kralik P
Sci Rep; 2017 Dec; 7(1):17501. PubMed ID: 29235545
[TBL] [Abstract][Full Text] [Related]
15. Development of a transferrin receptor-targeting HVJ-E vector.
Shimbo T; Kawachi M; Saga K; Fujita H; Yamazaki T; Tamai K; Kaneda Y
Biochem Biophys Res Commun; 2007 Dec; 364(3):423-8. PubMed ID: 17961511
[TBL] [Abstract][Full Text] [Related]
16. Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo.
Choi KM; Kim K; Kwon IC; Kim IS; Ahn HJ
Mol Pharm; 2013 Jan; 10(1):18-25. PubMed ID: 22663765
[TBL] [Abstract][Full Text] [Related]
17. Dual Surface Modification of Genome-Free MS2 Capsids for Delivery Applications.
Aanei IL; Francis MB
Methods Mol Biol; 2018; 1776():629-642. PubMed ID: 29869270
[TBL] [Abstract][Full Text] [Related]
18. A new RNA vaccine platform based on MS2 virus-like particles produced in Saccharomyces cerevisiae.
Sun S; Li W; Sun Y; Pan Y; Li J
Biochem Biophys Res Commun; 2011 Apr; 407(1):124-8. PubMed ID: 21362402
[TBL] [Abstract][Full Text] [Related]
19. Targeting of protease 2A genome by single and multiple siRNAs as a strategy to impair CVB3 life cycle in permissive HeLa cells.
Racchi G; Klingel K; Kandolf R; Grassi G
Methods Find Exp Clin Pharmacol; 2009 Mar; 31(2):63-70. PubMed ID: 19455260
[TBL] [Abstract][Full Text] [Related]
20. Chimeric capsid protein as a nanocarrier for siRNA delivery: stability and cellular uptake of encapsulated siRNA.
Choi KM; Choi SH; Jeon H; Kim IS; Ahn HJ
ACS Nano; 2011 Nov; 5(11):8690-9. PubMed ID: 21985460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
